Impact of tumor hypoxia and anemia on radiation therapy outcomes.

Local recurrence remains a major obstacle to achieving cure of many locally advanced solid tumors treated with definitive radiation therapy. The microenvironment of solid tumors is hypoxic compared with normal tissue, and this hypoxia is associated with decreased radiosensitivity. Recent preclinical data also suggest that intratumoral hypoxia, particularly in conjunction with an acid microenvironment, may be directly or indirectly mutagenic. Investigations of the prognostic significance of the pretreatment oxygenation status of tumors in patients with head and neck or cervical cancer have demonstrated that increased hypoxia, typically designated in these studies as pO(2) levels below 2.5-10 mm Hg, is associated with decreased local tumor control and lower rates of disease-free and overall survival. Hypoxia-directed therapies in the radiation oncology setting include treatment using hyperbaric oxygen, fluosol infusion, carbogen breathing, and electron-affinic and hypoxic-cell sensitizers. These interventions have shown the potential to increase the effectiveness of curative-intent radiation therapy, demonstrating that the strategy of overcoming hypoxia may be a viable and important approach. Anemia is common in the cancer population and is suspected to contribute to intratumoral hypoxia. A review of the literature reveals that a low hemoglobin level before or during radiation therapy is an important risk factor for poor locoregional disease control and survival, implying that a strong correlation could exist between anemia and hypoxia (ultimately predicting for a poor outcome). While having a low hemoglobin level has been shown to be detrimental, it is unclear as to exactly what the threshold for "low" should be (studies in this area have used thresholds ranging from 9-14.5 g/dl). Optimal hemoglobin and pO(2) thresholds for improving outcomes may vary across and within tumor types, and this is an area that clearly requires further evaluation. Nonetheless, the correction of anemia may be a worthwhile strategy for radiation oncologists to improve local control and survival.

[1]  X. Lin,et al.  Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. , 2001, Cancer research.

[2]  F. Eschwège,et al.  Variations in tumour oxygen tension (pO2) during accelerated radiotherapy of head and neck carcinoma. , 1998, European journal of cancer.

[3]  A. Giaccia,et al.  Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. , 1999, Cancer research.

[4]  M. Guichard,et al.  Efficacy of agents counteracting hypoxia in fractionated radiation regimes. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  J. Horiot,et al.  ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC). , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  J. Lutterbach,et al.  Anemia is associated with decreased local control of surgically treated squamous cell carcinomas of the glottic larynx. , 2000, International journal of radiation oncology, biology, physics.

[7]  M. Dewhirst,et al.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.

[8]  J. D. Chapman,et al.  Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age , 2000, Cancer.

[9]  C. Lautenschläger,et al.  Oxygenation of cervical cancers during radiotherapy and radiotherapy + cis-retinoic acid/interferon. , 1999, International journal of radiation oncology, biology, physics.

[10]  S. Keyes,et al.  Modification of the metabolism and cytotoxicity of bioreductive alkylating agents by dicoumarol in aerobic and hypoxic murine tumor cells. , 1989, Cancer research.

[11]  F. Bova,et al.  Prognostic and treatment factors affecting pelvic control of stage ib and iia‐b carcinoma of the intact uterine cervix treated with radiation therapy alone , 1984, Cancer.

[12]  T. Phillips,et al.  Clinical trials with etanidazole (SR-2508) by the Radiation Therapy Oncology Group (RTOG). , 1991, Radiotherapy and Oncology.

[13]  P J Eifel,et al.  Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. , 1999, The New England journal of medicine.

[14]  R. Lavey,et al.  Erythropoietin increases hemoglobin in cancer patients during radiation therapy. , 1993, International journal of radiation oncology, biology, physics.

[15]  I. Takata,et al.  Prognostic factors for patients with advanced non-small cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation. , 1996, Lung cancer.

[16]  D. Spelbring,et al.  Radiation therapy in the treatment of cervical Cancer: The university of Chicago/Michael reese hospital experience , 1990, Journal of surgical oncology.

[17]  Browning Jm,et al.  Tirapazamine: laboratory data relevant to clinical activity. , 1998 .

[18]  P. Vaupel,et al.  Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. , 1998, British Journal of Cancer.

[19]  G. Stuecklschweiger,et al.  Prognostic factors in patients with carcinoma of the uterine cervix treated with external beam irradiation and IR-192 high-dose-rate brachytherapy. , 1998, International journal of radiation oncology, biology, physics.

[20]  R. Bristow,et al.  T1/T2 GLOTTIC CANCER MANAGED BY EXTERNAL BEAM RADIOTHERAPY: THE INFLUENCE OF PRETREATMENT HEMOGLOBIN ON LOCAL CONTROL , 1998 .

[21]  C. Langer,et al.  Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Jayalakshmi,et al.  Mitomycin C adjuvant chemotherapy after Wertheim's hysterectomy for stage IB cervical cancer , 1989, Cancer.

[23]  W. Curran,et al.  Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. , 1995, International journal of radiation oncology, biology, physics.

[24]  B. Teicher,et al.  Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia. , 1995, Hematology/oncology clinics of North America.

[25]  G. Sroka-Perez,et al.  THE IMPACT OF BLOOD HEMOGLOBIN CONTENT ON THE OUTCOME OF RADIOTHERAPY : THE FREIBURG EXPERIENCE , 1998 .

[26]  J. Herman,et al.  Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis. , 1989, The Journal of urology.

[27]  A. Hanlon,et al.  Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study. , 2000 .

[28]  P. Glazer,et al.  Genetic instability induced by the tumor microenvironment. , 1996, Cancer research.

[29]  S. Rockwell,et al.  Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Trials. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Giraud,et al.  Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. , 1996, Radiology.

[31]  C. Willett,et al.  Time-dose considerations in the treatment of anal cancer. , 1997, International journal of radiation oncology, biology, physics.

[32]  H. Feldmann,et al.  Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[33]  A. Gerbaulet,et al.  Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. , 1989, International journal of radiation oncology, biology, physics.

[34]  C. Aquino-Parsons,et al.  Carbogen inhalation in cervical cancer: assessment of oxygenation change. , 1999, Gynecologic oncology.

[35]  J. Overgaard,et al.  Squamous cell carcinoma of the oropharynx: An analysis of 213 consecutive patients scheduled for primary radiotherapy , 1990, The Laryngoscope.

[36]  R. Sutherland,et al.  Mathematical modelling of oxygen supply and oxygenation in tumor tissues: prognostic, therapeutic, and experimental implications. , 1988, International journal of radiation oncology, biology, physics.

[37]  E. Dobrowsky,et al.  Response to preoperative concomitant radiochemotherapy with mitomycin C and 5-fluorouracil in advanced head and neck cancer. , 1989, European journal of cancer & clinical oncology.

[38]  T. Pajak,et al.  A phase I/II study of the hypoxic cell sensitizer misonidazole as an adjunct to high fractional dose radiotherapy in patients with unresectable squamous cell carcinoma of the head and neck: a RTOG randomized study (#79-04). , 1989, International journal of radiation oncology, biology, physics.

[39]  M. Eble,et al.  Rise of oxygenation in cervical lymph node metastasis during the initial course of radiochemotherapy , 1999, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[40]  S. Keyes,et al.  Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro. , 1985, Cancer research.

[41]  B. Vikram,et al.  Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. , 1998, International journal of radiation oncology, biology, physics.

[42]  L. Bastholt,et al.  A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[43]  J. Overgaard,et al.  Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. , 1989, International journal of radiation oncology, biology, physics.

[44]  S. Fosså,et al.  Blood tests and prognosis in bladder carcinomas treated with definitive radiotherapy. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[45]  R. Chapman,et al.  Collection and transfusion of blood in the United States, 1982-1988. , 1990, The New England journal of medicine.

[46]  J. Hermans,et al.  The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[47]  M. Akira,et al.  Definitive radiotherapy combined with high-dose-rate brachytherapy for Stage III carcinoma of the uterine cervix: retrospective analysis of prognostic factors concerning patient characteristics and treatment parameters. , 1998, International journal of radiation oncology, biology, physics.

[48]  I. Petersen,et al.  The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate. , 1989, International journal of radiation oncology, biology, physics.

[49]  P. Okunieff,et al.  Oxygen distributions partly explain the radiation response of human squamous cell carcinomas. , 1996, The British journal of cancer. Supplement.

[50]  P. Bergsjø,et al.  THE INFLUENCE OF ANEMIA ON THE RESULTS OF RADIOTHERAPY IN CARCINOMA OF THE CERVIX. , 1965, Radiology.

[51]  C. Dinney,et al.  Preoperative radiotherapy for muscle‐invasive bladder carcinoma. Long term follow‐up and prognostic factors for 338 patients , 1994, Cancer.

[52]  M. Dewhirst,et al.  Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[53]  R. Pötter,et al.  Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[54]  S. Keyes,et al.  Modulation of the cytotoxicity of mitomycin C to EMT6 mouse mammary tumor cells by dicoumarol in vitro. , 1988, Cancer research.

[55]  Janice M. Y. Brown,et al.  The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. , 1999, Cancer research.

[56]  P. Eifel,et al.  Figo IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. , 1999, International journal of radiation oncology, biology, physics.

[57]  L. Harrison,et al.  Prevalence of anemia in cancer patients undergoing radiation therapy. , 2001, Seminars in oncology.

[58]  B. Wollenberg,et al.  Changes in Head and Neck Tumor Hypoxic Fraction during Split-Course Radiochemotherapy , 1999, The Annals of otology, rhinology, and laryngology.

[59]  C. Dinney,et al.  Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone. , 1995, International journal of radiation oncology, biology, physics.

[60]  W. Millesi,et al.  10 Impact of hemoglobin (Hgb) level and use of recombinant human erythropoietin (r-HuEPO) on response to neoadjuvant chemoradiation therapy, tumor control, and survival in patients with oral or oropharyngeal squamous cell carcinoma (SCCA) , 1999 .

[61]  S. Rockwell,et al.  Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous‐cell carcinoma of the cervix , 2000, International journal of cancer.

[62]  R. Bush The significance of anemia in clinical radiation therapy. , 1986, International journal of radiation oncology, biology, physics.

[63]  J. Overgaard Sensitization of hypoxic tumour cells--clinical experience. , 1989, International journal of radiation biology.

[64]  A Dietz,et al.  Repeatability and prognostic impact of the pretreatment pO(2) histography in patients with advanced head and neck cancer. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[65]  S. Keyes,et al.  Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro. , 1985, Cancer research.

[66]  A. Fyles,et al.  Oxygenation predicts radiation response and survival in patients with cervix cancer. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[67]  L. Tuason,et al.  A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results , 1997, Head & neck.

[68]  D. Hirst What is the importance of anaemia in radiotherapy? The value of animal studies. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[69]  N. Sakuragi,et al.  High-dose-rate intracavitary irradiation using linear source arrangement for stage II and III squamous cell carcinoma of the uterine cervix. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[70]  S. Dische,et al.  Hemoglobin, radiation, morbidity and survival. , 1986, International journal of radiation oncology, biology, physics.

[71]  R. Pearcey,et al.  A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. , 2000, International journal of radiation oncology, biology, physics.

[72]  J. Overgaard,et al.  Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone. , 1995, Acta oncologica.

[73]  J. Overgaard,et al.  Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. , 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[74]  M Molls,et al.  Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. , 1999, International journal of radiation oncology, biology, physics.

[75]  B. Wouters,et al.  Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin , 1999, British Journal of Cancer.

[76]  D. Henry,et al.  Changing patterns of care in the management of anemia. , 1992, Seminars in oncology.

[77]  H. Lyng,et al.  Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis , 2000, British Journal of Cancer.

[78]  B. Maciejewski,et al.  Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglottic larynx. , 1997, International journal of radiation oncology, biology, physics.

[79]  A J Dembo,et al.  Definitive evidence for hypoxic cells influencing cure in cancer therapy. , 1978, The British journal of cancer. Supplement.

[80]  H. Sack,et al.  The effect of combined nicotinamide and carbogen treatments in human tumour xenografts: oxygenation and tumour control studies. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[81]  S. Rockwell,et al.  Mitomycin C: a prototype bioreductive agent. , 1994, Oncology research.

[82]  D. G. Grant,et al.  Pre-treatment anaemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy , 1999, The Journal of Laryngology & Otology.

[83]  U. Gatzemeier,et al.  Tirapazamine-cisplatin: the synergy. , 1998, British Journal of Cancer.

[84]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[85]  J. Ballinger,et al.  Imaging hypoxia in tumors. , 2001, Seminars in nuclear medicine.

[86]  S. Rockwell Oxygen delivery: implications for the biology and therapy of solid tumors. , 1997, Oncology research.

[87]  R. Pötter,et al.  Erythropoietin for patients undergoing radiotherapy: a pilot study. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[88]  J. Hong,et al.  The prognostic significance of pre- and posttreatment SCC levels in patients with squamous cell carcinoma of the cervix treated by radiotherapy. , 1998, International journal of radiation oncology, biology, physics.

[89]  B. Fenton,et al.  Enhancement of Tumor Perfusion and Oxygenation by Carbogen and Nicotinamide during Single- and Multifraction Irradiation , 2000, Radiation research.

[90]  B. Maciejewski,et al.  Clinical radiobiology of glottic T1 squamous cell carcinoma. , 1999, International journal of radiation oncology, biology, physics.

[91]  L. Solin,et al.  Prognostic factors in patients with bladder carcinoma treated with definitive irradiation , 1990, Cancer.

[92]  D. Siemann,et al.  Potentiation of cisplatin activity by the bioreductive agent tirapazamine. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[93]  M. Piérart,et al.  Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  P. Glazer,et al.  Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. , 2000, Cancer research.

[95]  C. Catton,et al.  Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. , 1991, International journal of radiation oncology, biology, physics.

[96]  L. Twiggs,et al.  Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. , 1994, International journal of radiation oncology, biology, physics.

[97]  R. Spiro,et al.  A prospective phase ii trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck , 1998, Head & neck.

[98]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[99]  B N Bundy,et al.  Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  M. Huncharek Meta-analytic re-evaluation of misonidazole in the treatment of high grade astrocytoma. , 1998, Anticancer research.

[101]  L. Peters,et al.  8 Extraordinary tumor control in phase I trial of concurrent tirapazamine cisplatin and radiotherapy for far advanced head and neck cancer , 1999 .

[102]  D. Alberts,et al.  Recombinant human erythropoietin (EPO) as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a southwest oncology group study , 2003 .

[103]  B N Bundy,et al.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. , 1999, The New England journal of medicine.

[104]  D I Rosenthal,et al.  A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[105]  P Vaupel,et al.  Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[106]  M. Höckel,et al.  Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. , 1993, Gynecologic oncology.

[107]  M Molls,et al.  Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. , 1998, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[108]  P. Schwartz,et al.  Pretreatment prognostic factors in carcinoma of the uterine cervix: a multivariable analysis of the effect of age, stage, histology and blood counts on survival. , 1983, International journal of radiation oncology, biology, physics.

[109]  J. Overgaard,et al.  Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. , 1989, International journal of radiation oncology, biology, physics.

[110]  S. Keyes,et al.  Modulation of the antineoplastic efficacy of mitomycin C by dicoumarol in vivo , 2004, Cancer Chemotherapy and Pharmacology.

[111]  C Weigel,et al.  Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. , 1998, International journal of radiation oncology, biology, physics.

[112]  J. Tworek,et al.  Bromodeoxyuridine alternating with radiation for advanced uterine cervix cancer: a phase I and drug incorporation study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  I. Pataki,et al.  Effect of hemoglobin on radiotherapy response in children with medulloblastoma: should patients with a low hemoglobin be transfused? , 1999, Medical and pediatric oncology.

[114]  P. Glazer,et al.  Mutagenesis induced by the tumor microenvironment. , 1998, Mutation research.

[115]  J. Widder,et al.  7 Continuous hyperfractionated accelerated radiotherapy and mitomycin C in head and neck cancer , 1999 .

[116]  M. Saunders,et al.  Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma , 1999, Cancer.

[117]  H. Madoc‐Jones,et al.  Prognostic factors for local and distant recurrence in stage I and II cervical carcinoma. , 1995, International journal of radiation oncology, biology, physics.

[118]  W. Dobrowsky Mitomycin C, 5-fluorouracil and radiation in advanced, locally recurrent rectal cancer. , 1992, The British journal of radiology.

[119]  D. V. Von Hoff,et al.  Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft , 1999, Cancer Chemotherapy and Pharmacology.

[120]  L. Harrison,et al.  Once‐weekly dosing of epoetin‐α increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy , 2003, Cancer.

[121]  N. Obralić,et al.  Prognostic importance of anemia related parameters in patients with carcinoma of the cervix uteri. , 1990, Acta oncologica.

[122]  J. Bussink,et al.  Clinical outcome and tumour microenvironmental effects of accelerated radiotherapy with carbogen and nicotinamide. , 1999, Acta oncologica.

[123]  P. Engstrom,et al.  Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. , 1991, International journal of radiation oncology, biology, physics.

[124]  D. Nicolae,et al.  Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial. , 1998, British Journal of Cancer.

[125]  C. Koch,et al.  Evaluation of the concept of "hypoxic fraction" as a descriptor of tumor oxygenation status. , 1997, Advances in experimental medicine and biology.

[126]  S. Spencer,et al.  Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study. , 1998, International journal of radiation oncology, biology, physics.

[127]  S. Dische,et al.  Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. , 1996, The British journal of cancer. Supplement.

[128]  F. George,et al.  Association of hemoglobin levels before and during radiotherapy with prognosis in uterine cervix cancer. , 1973, Radiology.

[129]  D. Hirst,et al.  Anemia: a problem or an opportunity in radiotherapy? , 1986, International journal of radiation oncology, biology, physics.

[130]  S. Dische Radiotherapy and anaemia--the clinical experience. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[131]  R. Lavey Clinical trial experience using erythropoietin during radiation therapy. , 1998, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[132]  D. Dunlop,et al.  Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  W. Millesi,et al.  Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. , 1998, International journal of radiation oncology, biology, physics.

[134]  B N Bundy,et al.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. , 1999, The New England journal of medicine.

[135]  A. Mundt,et al.  Race and clinical outcome in patients with carcinoma of the uterine cervix treated with radiation therapy. , 1998, Gynecologic oncology.

[136]  S. Keyes,et al.  Preclinical studies of porfiromycin as an adjunct to radiotherapy. , 1988, Radiation research.

[137]  T. Inoue,et al.  High-dose rate intracavitary therapy for carcinoma of the uterine cervix: I. General figures of survival and complication. , 1987, International journal of radiation oncology, biology, physics.

[138]  Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. , 1995 .

[139]  C. Reynolds,et al.  Towards new transition metal-based hypoxic selective agents for therapy and imaging. , 2001, Journal of inorganic biochemistry.

[140]  J. Overgaard,et al.  Modification of Hypoxia-Induced Radioresistance in Tumors by the Use of Oxygen and Sensitizers. , 1996, Seminars in radiation oncology.

[141]  P. Grigsby,et al.  Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: final results of RTOG 80-05. Radiation Therapy Oncology Group. , 1999, International journal of radiation oncology, biology, physics.